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Background/Aim: Vitamin B12 has multiple functions within the human body, including 
roles as a co-factor for both the one carbon metabolism cycle and methylmalonyl CoA 
mutase. Vitamin B12 deficiency can have serious lifelong consequences. The aim of this 
study is to explore the associations between markers of vitamin B12 status and other 
biochemical, dietary and physical measures. 
Methods: Three data sets composed of either young omnivore women (n=65; age 24.5 ± 
4.4 y; mean ± SD), randomly selected young women (n=305; age 22.5 ± 3.9) and elderly 
women (n=44; age 80.5 ± 7.6) were examined. Associations between vitamin B12 
biomarkers and other selected biomarkers of nutritional status (i.e. serum folate, 
erythrocyte folate), lifestyle factors such as; dietary intake, alcohol intake, oral 
contraceptive pill (OCP) use (in the non-elderly groups), and other factors such as BMI 
were examined using mixed effects regression, accounting for study clusters. 
Results: Serum vitamin B12 stratification (low, medium or high) was not associated with 
likelihood of being classed as having a raised methylmalonic acid (MMA) and/or 
homocysteine (tHcy) (p=0.316). Younger women who used the OCP had serum vitamin 
B12 concentrations that were 72.3 (SE=12.4) pmol/L lower than non-users (p<0.001), 
there was however no associations between OCP use and tHcy (p=0.669) or MMA 
(p=0.595) concentrations. Serum vitamin B12 concentration (pmol/L) was related 
positively to both serum folate (nmol/L) (β=0.018 95% CI: 0.009, 0.026, p<0.001) and 
erythrocyte folate (nmol/L) (β =0.456 95% CI: 0.164, 0.747, p<0.01). Vitamin B12 was 
marginally associated with the intake of protein (p<0.05) and negatively associated with 
alcohol intake (p<0.001).  
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Conclusions: The lack of an association between serum vitamin B12 stratifications and 
metabolite cut-offs suggest that you are not more likely to have raised metabolites in 
conjunction with any of the three serum vitamin B12 cut-offs. The lack of negative 
metabolite consequences in those who use the OCP suggest that the decreased serum 
vitamin B12 is possibly inconsequential. This, however, suggests that in populations who 
are frequent users of the OCP, serum vitamin B12 may not be suitable as a primary 
measure of vitamin B12 status. Alcohol use in Australia females is above the global 
average and suggests that this group are at increased risk of decreased vitamin B12 status 
due to alcohol intake. Serum vitamin B12 proved less than ideal throughout this study as a 
primary marker of vitamin B12 status. It was unable to show concordance with MMA and 
tHcy cut-offs and demonstrated it was unsuitable as a primary marker in OCP users. This 
suggests that it is time for a new primary marker of status with holo-transcobalamin II 
being the likely successor. Research needs to be focused on this marker of status in the 
future to determine the factors which affect it so we can be better suited to use it as a 
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Chapter One: Introduction 
In the early 1900’s pernicious anaemia was a perplexing and harmful medical diagnosis 
that would not see a potential treatment until 1926. Minot and Murphy announced they had 
cured 45 patients of their pernicious anaemia by persuading them to consume a diet 
containing up to half a pound of beef liver per day (1). The source of treatment in beef 
liver was termed vitamin B12 and the discovery of its complete structure eventuated in 
1956 by a team lead by Dorothy C. Hodgkin (2). She would later receive the Nobel Prize 
in Chemistry for her work in determining the structures of important biochemical 
substances. 
In the present we have three main markers of vitamin B12 which are commonly used to 
determine an individual’s vitamin B12 status (3-5). The three main measures are serum 
vitamin B12, homocysteine (tHcy), and methylmalonic acid (MMA). While serum vitamin 
B12 is considered the primary marker of status, tHcy and MMA are considered to be 
appropriate for monitoring change following vitamin B12 supplementation/treatment. The 
three markers have also been combined in a possible method for determining a subclinical 
deficiency state (3). 
This being said, all three markers of status have their own flaws. Serum vitamin B12 
measures vitamin B12 in sera which is both; metabolically available (holo-transcobalamin 
II) and metabolically unavailable (holohaptocorrin) (4, 5). This opens up the possibility for 
holohaptocorrin to falsely infer deficiency or inversely mask true deficiency. 
Homocysteine is also affected by many other factors other than vitamin B12. Folate and 
renal status among others affect tHcy levels more than do vitamin B12; as such levels of 
this marker must be further interpreted before classification of vitamin B12 deficiency (4, 
5). Methylmalonic acid can be falsely increased in the elderly and those with renal 
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impairments (4). While these are the main causes of variation, they account for only a 
small proportion of variation.
The reliance of serum vitamin B12 as our primary measure of status is a potentially 
negative tendency given its uncertainties. New techniques have given us the ability to 
accurately measure holo-transcobalamin II (holo-TC II). While this method is now more 
available we need to further understand the factors which affect it, requiring ongoing 
research. 
Currently there is no gold standard measure of vitamin B12 deficiency, a factor which 
limits our ability to recognise and diagnose deficiency. As such it is important to determine 
how the markers of status have been used to determine deficiency in the past and how they 
could potentially be used in the future.  
Outside of the biomarkers of status it is important to determine which factors may be 
affecting vitamin B12 status in our study population. Factors of particular importance 
include use of an oral contraceptive pill (OCP) and alcohol intake. It is also important to 





Chapter Two: Literature Review 
2.1 Background 
2.1.1 History 
Early in the previous century, hospitals around the world began to experience an increase 
in the recognition of a perplexing form of anaemia which carried dire consequences for 
those affected (6). The outlook for these individuals despite the occasional slight 
improvement in treatment, was by no means positive (6). This anaemia had aptly been 
named “pernicious anaemia” because of its harmful and at the time deadly effect (6). In 
1908, Richard C. Cabot (7), analysed the time of survival in 1200 such patients and found 
that survival following the onset of said disease was generally from one to three years. His 
results also showed that in only six patients of the 1200, was permanent recovery 
witnessed (7). It wasn’t until 1926 that the medical world was stunned by a potential 
treatment. Minot and Murphy (1) announced that they had effectively eliminated the 
anaemia in a group of 45 patients by persuading them to eat for some months, a diet that 
contained up to half a pound of beef liver daily. 
Following the announcement of Minot and Murphy, purified beef liver extracts were 
produced (6) with continuing improvement until in 1948 when the source of activity in 
pernicious anaemia treatment present in beef liver was discovered and published. The 
source of activity was identified as crystalline cyanocobalamin by Karl Folkers and 
associates (8), and then again only a few weeks later by Smith and Parker (9). The active 
substance was termed “Vitamin B12.” Following its isolation, exhaustive research over a 
decade by many investigators resulted in the discovery of the complete structure of vitamin 
B12. This was completed in 1956 by Dorothy C. Hodgkin’s group (2) and she was later 
awarded the Nobel Prize in Chemistry for her efforts in 1964. The structure of vitamin B12 




Figure 1 Structure of Vitamin B12 (10) 
2.1.2 Physiology and Function 
Stepping forward in time, our understanding of vitamin B12 and the way it is processed 
and absorbed has progressed remarkably. The mechanism by which vitamin B12 is 
absorbed into the body is complex and is outlined in Figure 2. Vitamin B12 under normal 
circumstances is introduced to the body bound to protein following the ingestion of food. 
In the stomach vitamin B12 is cleaved from protein by gastric pepsin (11) produced in the 
parietal cells. The parietal cells also produce and secrete intrinsic factor (IF), another 
essential factor related to vitamin B12 absorption (12). Unbound vitamin B12 within the 
stomach is then preferentially bound by haptocorrin (TC I) (11). Degradation of TC I 
occurs in the upper intestine by pancreatic proteases as it leaves the stomach (13). The 
rereleased vitamin B12 is now available to be bound by IF forming an IF-vitamin B12 
complex (13). This complex travels through the intestine to the ilium, where it is taken up 
by the IF receptor, cubilin, located on gut epithelial cells (14). The IF-vitamin B12 
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complex is degraded in the ileal cell endosome releasing vitamin B12, which eventually 
reaches the abluminal surface of the ileal cell and enters the bloodstream attached to 
transcobalamin II (TC II) (15). 
 
Figure 2 Absorption of vitamin B12 process (10) 
Vitamin B12 has two known functions in the human body, including serving as a cofactor 
in the methylation of homocysteine to methionine, and as a cofactor in the rearrangement 





2.2 Biochemical Assessment of Vitamin B12 Status 
 
Methods of diagnosing vitamin B12 deficiency fall into one of two categories, these being: 
measures of vitamin B12 amounts (i.e. serum vitamin B12 or holo-TC II); or measures of 
functional metabolic status, such as vitamin B12 metabolite biomarkers (i.e. MMA or 
tHcy) (4). Currently no diagnostic gold standard for vitamin B12 status exists (4). See 
Table 1 for collated information on vitamin B12 status measures. 
Table 1 Biomarkers of Vitamin B12 status with cut-offs for deficiency 
 
2.2.1 Serum Vitamin B12 
Serum vitamin B12 is the measure of total vitamin B12 in the sera of an individual. This 
includes both holo-haptocorrin and holo-TC II (5, 16). Measurement of serum vitamin B12 
is currently the most commonly used method for evaluating status (5), there is however 
much disagreement about the reliability of this method and some studies have shown 
systematic overestimates of vitamin B12 status in individuals with established deficiency 














< 148 pmol/L 12, 13, 19 
MMA Blood Sera Gas chromatography-
mass spectrometry 
> 270 nmol/L 12, 19 
tHcy Blood Plasma Enzyme Immunoassay > 10 μmol/L 12, 13, 22 
Holo-TC II Blood Sera 2-step sandwich 
microparticle enzyme 
immunoassay 
< ~40 pmol/L 29, 30 
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The earliest employed methods of serum vitamin B12 analysis relied on microorganisms. 
The growth of these organisms was proportional to the content of vitamin B12 in an 
individual’s sample, allowing the determination of the content of vitamin B12 in the 
sample (20). The current test for serum vitamin B12 is widely available, as well as being 
relatively cheap (5). It uses an automated method and competitive-binding immune 
chemiluminescence (5). 
It is suggested by some that a serum vitamin B12 level of <148 pmol/L is sensitive enough 
to diagnose 97% of patients with deficiency (5), and this appears to be a similar cut-off 
that the majority of studies have employed since cut-offs were impossibly low in the 
1950’s (21). Carmel reported (4) that some investigators raised the cut-off of deficiency 
from 148 to 258 pmol/L in order to ensure no case of deficiency be missed (4). The gross 
over-diagnosis of this change was substantial and MMA and tHcy results of these patients 
suggest that two thirds of the newly classified deficient patients had suspect results. 
Furthermore, very few of the remaining one third had clinical deficiency (4).  
As only approximately 20-30% of the vitamin B12 in serum is in the holo-TC II form (16), 
the serum vitamin B12 test may mask true deficiency or falsely infer a deficient state. The 
high amounts of holo-haptocorrin which are largely metabolically unavailable can mask 
the true amount of holo-TC II, conversely a low holohaptocorrin concentration may imply 
deficiency when levels of the available holo-TC II are sufficient for metabolic processes 
(5, 16, 21). This fact renders the serum vitamin B12 test potentially unreliable. 
2.2.2 Methylmalonic Acid 
The conversion of L-methylmalonyl-CoA to succinyl-CoA relies on the interaction of 
methylmalonyl-CoA mutase and its cofactor vitamin B12 (in the form of 5’-
deoxyadenosylcobalamin). In the absence of vitamin B12, D-methylmalonic acid (MMA) 
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accumulates in the body (4, 21). It is for this fact that MMA can be used as an indicator for 
vitamin B12 status.  
Analysis of MMA begun in the late 1950’s (21) when it became possible to look at the 
amount of MMA in pooled samples of urine. Moving forward in time, more sensitive 
methods of MMA analysis appeared and made it possible to measure small amounts of 
serum with increasing accuracy and precision (22, 23). Currently, MMA can be measured 
reliably by gas chromatography-mass spectrometry (21).  
Reference cut-offs for MMA vary widely but the most commonly applied cut-off is ~270 
nmol/L, with many laboratories defining cut-offs based on two or three standard deviations 
from the mean (~270 or 370 nmol/L respectively). While 270 nmol/L is the most common 
cut-off, there is much variation with levels ranging from 210 - 370 nmol/L (21). 
Many experts currently see MMA as the best metabolic test available for confirmation of 
vitamin B12 deficiency, with normal MMA levels providing compelling evidence to 
disprove deficiency (4). There are however limitations of MMA measurements which 
occur in older patients (>65) and those with renal impairments. In these individuals levels 
can be falsely increased. These two factors are the main causes of variation but still only 
explain a small proportion of variation. Still, high levels of MMA can usually be explained 
by vitamin B12 deficiency, especially if coupled with symptoms of deficiency. 
2.2.3 Total Homocysteine 
Increased plasma tHcy, like MMA is a marker of vitamin B12 deficiency and indicates 
impaired methionine synthase activity (4). Furthermore, elevated tHcy concentrations are 
weakly associated with an increase in cardiovascular disease (CVD) risk. However, 
causality remains uncertain (24, 25). Like MMA, tHcy is used for monitoring changes 
following vitamin B12 therapy (21) and it has comparable sensitivity to MMA (4, 21). 
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Questions are raised about tHcy’s ability to be considered as a biomarker for vitamin B12 
status however due to other factors affecting levels. Both folate status and renal status 
affect tHcy levels more than that of vitamin B12 (26), and there are many other factors 
which raise tHcy, such as vitamin B6 status and hyperthyroidism (5).  
Nevertheless, cut-offs for tHcy are defined and plasma levels of tHcy lower than 10 
μmol/L are considered optimal (4). Many laboratories however use cut-offs of 12 to 14 
μmol/L in adult men and 10 to 12 μmol/L in premenopausal women (4). A recent review 
by Hunt et al. states that the cut-off used also depends on the individual technique utilised 
to measure tHcy, and suggests that a cut-off of 15 μmol/L should be regarded as high (5). 
2.2.4 Holo-Transcobalamin II 
Holo transcobalamin II is the complex of the serum transport protein TC II with attached 
vitamin B12 (27). Transcobalamin II has an important role in the blood, but small 
quantities are also found in other fluids (i.e. milk, cerebrospinal fluid, semen) (28). 
Vitamin B12 is rapidly delivered to the tissues of the body by Holo-TC II as it has a 
relatively short plasma half-life of around 90 minutes (compared to the holo-haptocorrin I 
half-life of 9-10 days) (29). 
It was first postulated in 1983 (30) that the measurement of holo-TC II may result in a 
more accurate measure of vitamin B12 status than its predecessor, total vitamin B12.  It 
was not until 2002 that reliable methods of analysis surfaced in the forms of an enzyme-
linked  immunosorbent assay (31) and a radioimmunoassay (32). Holo-TC II assays are 
now more accurate and a fully automated method developed in 2008 (33) has become 
commercially available. 
As with other measures of vitamin B12 status, reference limits vary and a standard level is 
not available. One study evaluating laboratory performance (34) compared available data 
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from 8 studies. These studies reported lower limits of healthy holo-TC II ranging from 11-
41 pmol/L (34). The authors summarised that a lower limit of ~40 pmol/L was most likely 
the best estimate of a healthy status (34). The fully automated method developed in 2008 
however identified a 95% CI cut-off of only 19 pmol/L (33). 
Low concentrations of holo-TC II can indicate one of two things; firstly that there is 
impaired transfer of holo-TC II from the ileal cell into the bloodstream (vitamin B12 
malabsorption), and secondly that there is insufficient availability of vitamin B12 for 
tissues (metabolic insufficiency) (35). As both of these indications have merit (36), the 
analysis of holo-TC II is rendered unspecific for diagnosing one problem over the other. 
2.2.5 Summary 
The above information highlights the lack of clarity available in the classification of 
vitamin B12 status. Without specific cut-offs, diagnosis of deficiency without symptoms 
becomes more difficult. Using combinations of vitamin B12 markers has been suggested 
by both Carmel & Sarrai (3) and Bailey et al (37). in the past with Carmel & Sarrai (3) 
suggesting that a composite criteria be utilised, in which serum vitamin B12 < 148 pmol/L, 
or 148-258 pmol/L and MMA  > 0.3 μmol/L, or tHcy > 13 μmol/L (female) and > 15 
μmol/L (male) be used to indicate inadequate vitamin B12 status. Bailey et al. opted to use 
both serum vitamin B12 and MMA results to analyse results from the NHANES data (37). 
Another recent clinical review by Hunt et al. (5) outlined the clinical diagnosis and 
management of vitamin B12 deficiency including a serum vitamin B12 cut-off for 




2.3 Nutrition and bioavailability 
2.3.1 Food sources 
Vitamin B12 is synthesised by certain bacteria and archaea (38). Animals that ingest said 
microorganisms then absorb and concentrate the produced vitamin B12 in their tissues 
(39). Plants do not provide a naturally occurring bioactive form of vitamin B12, some 
plant foods may contain added vitamin B12 while others such as mushrooms contain 
vitamin B12 analogues which are inactive in humans and as such provide no nutritional 
benefit (39).  However some studies have shown that dried green and purple algae (nori) 
may contain vitamin B12 which may be active (39), while other edible algae contain only 
trace or no vitamin B12 (39). Furthermore, certain types of Japanese seaweeds have 
prevented deficiency in vegans (40). Excluding nori, active vitamin B12 is found only in 
foods originating from an animal source (41). See appendix A for a compiled list of 
vitamin B12 containing foods, including a more in depth analysis of vitamin B12 contain 
foods.  
2.3.2 Bioavailability 
Currently there appears to be limited information on the bioavailability of vitamin B12 in 
humans. What is known however is that in the average human the absorption of vitamin 
B12 has been shown to have varying results based on the type and quantity of protein that 
is consumed (41). Vitamin B12 from whole foods shows us that there appears to be 
different absorption rates with certain foods having much higher absorption than others, 
for example, studies show that chicken (42) and fish (43) have relatively high absorption 
(≥61% and  ≥30% respectively) when compared to another common vitamin B12 source 
such as eggs (3.7-9.2%)  (44). The main limiting factor in vitamin B12 absorption is an IF-
mediated system which limits the amount of vitamin B12 that can be absorbed from a 
single oral dose to around 1.5-2.0 μg (20). The limiting factor is likely to be the number of 
ileal receptors rather than available IF, as this is produced in abundance by the body (20). 
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Appendix B gives an adapted insight into bioavailability of certain animal products from 
O’Leary & Samman (45). 
2.4 Vitamin B12 Requirements 
The current Nutrient Reference Values for Australia and New Zealand (46) state that for 
both male and female adults, the RDI of vitamin B12 is 2.4 μg/day. The RDI for pregnant 
females is slightly higher (2.6 μg/day) to account for foetal and placental needs. The RDI 
for lactating women is slightly higher again (2.8 μg/day) to account for the average amount 
of vitamin B12 secreted in breast milk per day. These levels mirror those of the United 
States RDA values for vitamin B12 set by the Institute of Medicine (47). The US 
recommendations state that the RDA is based on the amount needed for the maintenance 
of normal serum B12 levels and haematological status (i.e. the prevention of megaloblastic 
anaemia). 
The elderly are the population who are the most susceptible to vitamin B12 deficiency (48, 
49). Their susceptibility lies in their greater development of gastritis, food-bound 
cobalamin malabsorption and pernicious anaemia (20, 48, 50) rather than B12 restricted 
diets. As such, both US and Australia/New Zealand reference publication suggest that the 
elderly should meet the majority of their RDA/RDI by consuming; foods rich in vitamin 
B12, foods fortified with vitamin B12 or a vitamin B12 containing supplement (47).  
One study however, suggests the need for a change in the daily requirements of vitamin 
B12 (51). This study concluded that a daily intake of 4-7 μg/day is more appropriate than 
the current recommendations for maintaining optimal vitamin B12 and biomarker status. 
This is backed up by the knowledge that clinical features of deficiency can manifest in the 
absence of anaemia or low serum vitamin B12 levels (52, 53). The European Food Safety 
Authority Panel on Dietetic Products, Nutrition and Allergies recently suggested an 
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adequate intake reference value of 4 μg/day based on data from different biomarkers of 
status (54). 
There is at this time insufficient evidence to set an upper limit of vitamin B12 intake. It is 
thought that this may result from the gastrointestinal tracts limited ability to absorb 
vitamin B12, effectively preventing excess intake. This does not account for vitamin B12 
supplements given by injection of sublingual routes however, as these methods bypasses 
the gastrointestinal limiting factor.  
2.5 Deficiency State 
The most common clinical expression of vitamin B12 deficiency presents in the form of 
megaloblastic anaemia, which affects all blood cells (not just red-blood cells). Symptoms 
of megaloblastic anaemia are vast including but not limited to; fatigue, muscle weakness 
and nausea (20). The role of vitamin B12 in the causes of megaloblastic anaemia is 
complex and outside of the scope of this study, and as such will not be discussed. An 
expert understanding can be gained in the work of Chanarin (20). 
Prolonged vitamin B12 deficiency has long been known for its role in the development of 
subacute combined degeneration of the spinal cord (55). This degenerative disease leads to 
progressive parathesis, incoordination, impaired sensation, and other neurological issues 
through its effect on myelin sheaths in the spinal cord (4, 56). Neurological abnormalities 
will respond to vitamin B12 therapy if caught early enough (4). In cases where deficiency 
is left untreated for an extended period, only partial response can be achieved with the 
possibility of complete irreversibility (4). 
Currently, elevated tHcy concentrations are considered a risk factor for CVD (24, 25). The 
majority of research into CVD and tHcy focuses on the effect of folate with or without the 
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addition of vitamins B12 and B6, whereas investigations into the effects of vitamin B12 on 
CVD risk are limited (45).  
2.6 Deficiency Causes 
There are a multitude of reasons why vitamin B12 deficiency may develop in an 
individual. These causes have varying levels of severity and can be categorised into severe 
malabsorption, mild malabsorption, and dietary deficiency (57). Deficiency develops over 
an extended period of time due to the relatively large vitamin B12 stores in the body. Daily 
loses are approximately ~1 μg/day (4). With a body store of around 2500 μg (4), 
deficiency develops over many years rather than days. Deficiency will develop more 
quickly in those who have both malabsorption issues and dietary deficiency.  
2.6.1 Severe Malabsorption 
The most common cause of severe malabsorption is due to the effects of pernicious 
anaemia (4, 57). This anaemia is an autoimmune gastritis caused by the destruction of 
gastric parietal cells (4). As parietal cells are the source of IF production, this causes a 
major problem in the ingestion of vitamin B12. Without the required IF, vitamin B12 can 
only be absorbed by passive diffusion, which accounts for approximately 1-3% (58) in a 
healthy individual. Similar effects are seen when there is total/partial gastrectomy, or 
gastric bypass/bariatric surgery (57). These procedures can result in the loss of gastric acid 
necessary for the cleaving of food bound vitamin B12 and like pernicious anaemia the loss 
of IF (59). Intestinal causes of severe malabsorption are related to disorders of the ileum. 
Total or partial resection of the ileum results in total or partial loss of the IF-receptor 
cubilin, which results in the loss or limiting of the ability to absorb the IF-vitamin B12 
complex from the gastrointestinal contents (59). Imerslund-Gräsbeck is a hereditary cause 
of vitamin B12 malabsorption. This syndrome arises from the mutation of the gene for 
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cubilin or the gene for amnionless (required for the endocytosis of the IF- vitamin B12 
complex) (4) .  
2.6.2 Mild Malabsorption  
Atrophic gastritis is a condition which develops gradually over time due to the 
inflammation of the stomach lining (45). This extended inflammation eventually destroys 
cells in the stomach lining, which decreases the secretion of both gastric acid, necessary 
for releasing protein bound vitamin B12, and IF. Atrophic gastritis prevalence increases 
with age and is common in the elderly (45). 
Another common cause of mild malabsorption results from the use of medications. 
Extended periods of metformin use are associated with low vitamin B12 levels (4), the 
mechanism for this is still poorly documented however. Other common medications 
include those used to block stomach acid secretion in the event of gastric reflux or stomach 
ulcer production, such as proton pump inhibitors and H2 receptor antagonists (4, 57). 
These drugs result in a decreased ability to cleave food bound vitamin B12 resulting in a 
decrease in the amount of vitamin B12 available to bind with IF. 
2.6.3 Dietary Deficiency 
Dietary deficiency results from the avoidance of foods containing vitamin B12. This 
typically arises in vegans who eat no meat or animal products and to a lesser extent 
vegetarians (although this subgroup can still get vitamin B12 from animal products such as 
dairy products and eggs) (45). These individuals can instead meet their requirements by 
consuming fortified foods such as yeast or by taking supplements (45). Infant vitamin B12 
deficiency can result from breast feeding in mothers who are themselves deficient, thus 
limiting the amount of vitamin B12 secreted in the breast milk (57).  
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2.6.4 Other Factors Affecting Vitamin B12 Levels 
In the past, studies have shown lower concentrations of vitamin B12 in OCP users 
compared to non-users (60, 61). Theories for this change include a false indication of 
deficiency (62) and a redistribution of vitamin B12 among transporters (63).  
Following an 8 week crossover intervention with red wine and vodka, Gibson et al (64) 
showed that a two week alcohol intervention significantly decreased serum vitamin B12 
levels and increased plasma tHcy. In 2014, the World Health Organisation (WHO) global 
status report on alcohol and health (65) reported an alcohol intake per capita (aged 15+) 
consumption (in litres of pure alcohol) of 12.2 L for Australia. It also reported a 
breakdown of males and females per capita with females consuming 7.2 L/year or 15.6 
g/day (pure alcohol). Both the per capita and female per capita results were above the 
global average alcohol intake of 6.2 L per year. These results highlight the increased 
alcohol intake in the Australian population and may prove an issue for vitamin B12 levels. 
Multiple studies have found an inverse relationship between BMI and vitamin B12 
concentrations in children (66, 67). Of interest is determining if this relationship holds true 
into adult years and why such a relationship may exist. 
2.7 Conclusion 
Since pernicious anaemia was first cured in the early 1900’s, our understanding of vitamin 
B12 has progressed dramatically. We now understand its role in the body and have a 
greater appreciation of the consequences of deficiency. While our knowledge of vitamin 
B12 has progressed, we are still lacking a gold standard measure of deficiency. Of the 
three common markers used for vitamin B12 deficiency, each has both positive and 
negative aspects of its use including a lack of clearly defined cut-offs of deficiency. 
Neurological impairment as a result of vitamin B12 deficiency is a serious consequence of 
a lack of understanding and one that we should endeavour to avoid at all costs. It is 
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because of such serious outcomes that we must continue to drive the evolution of 
understanding in the area of vitamin B12 through ongoing research. A greater 
understanding of deficiency markers and the interconnected relationships of markers is 
required in the search for clearly defined cut offs and the potential development of a gold 




Chapter Three: Objective statement 
Currently there is no gold standard measure of vitamin B12 status. We have multiple 
markers of status including both direct and functional markers which have different factors 
affecting their reliability. There are many dietary factors as well as other factors which are 
associated with vitamin B12 status. This study is focused on compiling three data sets 
from studies completed in women from Sydney, Australia. From here we are interested in 
using the compiled data with aims to: 
1. Assess the Vitamin B12 status of younger and older Australian women. 
2. Determine the association of folate status on vitamin B12 biomarkers. 
3. Determine the association of the OCP on vitamin B12 status. 
4. Explore the association between total protein intake and vitamin B12 status. 
5. Explore the association between total energy intake and vitamin B12 status. 
6. Explore the association of alcohol on vitamin B12 status. 




Chapter Four: Methods 
For our secondary analysis we used data from three studies based in Sydney, Australia. 
The three studies have been given abbreviations owing to a particular characteristic of 
each, namely; elderly participants (ELD), omnivores (OMN), and randomly selected 
participants (RND), respectively. The methods for our study are broken into two main 
sections, discussing both the designs and procedures of the primary studies we have used 
and the statistical methods employed during the analysis of the combined data set. A full 
breakdown of the ELD, OMN and RND studies individual methods have been published 
by O’Leary et al. (68), McArthur et al. (69), and Fayet et al. (70) respectively.  
4.1 Study Designs 
4.1.1 Recruitment 
Recruitment of participants differed between the three studies, with different methods 
being employed as well as a range of participants being recruited. The ELD study was 
completed in a 48-bed sub-acute geriatric rehabilitation unit; this was also a part of a larger 
study examining nutritional status and drug-interactions on vitamin B12 status. Both the 
OMN and RND studies recruited participants through various methods at the University of 
Sydney campus. Inclusions for the studies were newly admitted, English patients aged 60+ 
without dementia (ELD), and females aged 18-35 (OMN and RND). Exclusion criteria for 
the ELD study included; having a condition affecting the absorption of vitamin B6, 
vitamin B12 or folate, untreated hypothyroidism, active neoplasm, renal impairment, or 
were taking B vitamin supplements/injections. Exclusions for the OMN and ELD studies 
were similar to each other, with both studies excluding individuals who were 
pregnant/lactating, or were consuming nutritional supplements or medications (excluding 
the oral contraceptive pill). Differences between the two studies were exclusions in the 
OMN study of individuals who; were vegetarian or had a reported major illness, and in the 
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RND study of individuals who; had a diagnosed eating disorder, were elite athletes, or 
were not enrolled as students. Approval for the ELD study was given by the Calvary 
Health Care Sydney Ethics Committee, while approval for the OMN and RND studies was 
given by the University of Sydney Human Ethics Committee.  
4.1.2 Nutrient analysis 
Dietary analysis was completed in all three studies using a food frequency questionnaire 
(FFQ). All three FFQs were based on the Blue Mountains Eye Study semi-quantitative 
food frequency questionnaire. An FFQ which was validated in an elderly population using 
weighed diet records (71). This FFQ was not validated for use in the ELD study as it was 
assumed the population in which it was validated for (71) was similar enough to the target 
population to not require revalidation. For the FFQ to be used in the OMN and RND 
studies however, it needed to be validated in a similar population due to the overwhelming 
differences between the two study populations and the Blue Mountains Eye Study 
population. This was completed in a prior validation study by Fayet et al (72) and showed 
that the FFQ was an appropriate tool for use in a younger female population.  
Dietary data analysis was completed in two ways; firstly the ELD study used FoodWorks 
Xyris software (2005 Professional Edition) which utilised the Australian Food and 
Nutrient Database (AUSNUT99). Missing nutrient data was added manually based on The 
British Tables of Food Composition. For both the OMN and RND studies, the average 
daily nutrient intake was calculated using purpose built software (Microsoft Access 2007) 
which was linked to the Australian Food Composition database (NUTTAB 2006) (73). 
 
4.1.3 Blood sampling and testing 
In all three studies, blood samples were collected from an antecubital vein while subjects 
were in a fasted state (10-12 hours). Collection of samples occurred between the hours of 
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0600 and 0830 for the ELD study and between 0730 and 0930 for the OMN and RND 
studies. Samples were collected into vacutainer tubes (Becton Dickinson, Franklin Lakes, 
NJ, USA), which were either EDTA-coated or untreated, dependent on the analysis to be 
run. 
In all three studies; serum vitamin B12, serum folate and erythrocyte folate were analysed 
using an automated system (UniCel Dxl Immunoassay System, Beckman Coulter Inc., 
Brea, CA). Both the ELD and RND studies used the same methods for determining tHcy 
and MMA. High performance liquid chromatography (Homocysteine HPLC Kit, BioRad, 
Munich, Germany) with fluorescence detection (Waters, Milford, MA, USA) was used to 
determine serum tHcy. Serum MMA was measured in both studies by liquid 
chromatography-tandem mass spectrometry with electrospray ionization as previously 
described (74, 75). 
4.2 Statistical Methods 
All statistical analysis was completed using Stata V14.0. Diet energy was reported in two 
forms between the three groups (kcal and kJ); as such the ELD group diet energy was 
converted from kcal to kJ using a conversion factor of 4.184. All men from the ELD group 
(n=11) were excluded to give continuity between the three groups and to give clearer 
application for any results found. Further exclusions included two individuals with 
multiple skewed results and a replacement of one individual’s MMA result with a missing 
value due to being twice the next highest value. Histograms and box plots of variables 
(age, BMI, serum folate, erythrocyte folate, serum vitamin B12, serum tHcy, serum MMA, 
dietary energy, and dietary protein) for each group were plotted to assess normality, and 
determine any apparent skew or identify outliers within the data sets. Variables which 
were determined visually to be skewed were log transformed for statistical testing 
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purposes. Potential outliers were further investigated to determine if they were acceptable 
or required exclusion from the data set because of likely error.   
Descriptive statistics for demographic, biochemical and some dietary intake variables were 
calculated for each of the groups (mean(SD) for continuous and n(%) for categorical). 
Oneway ANOVA with an F-test and chi-squared tests determined if continuous variables 
were different between the groups. 
New categorical variables were created to assess the vitamin B12 status of the data set. 
Multiple cut-offs were utilised from two different sources (3, 5). Two methods were 
utilised to assess serum vitamin B12 levels, the first used a cut-off of 148 pmol/L (5). The 
second method used three different categories for serum vitamin B12 being; >258 pmol/L, 
148-258 pmol/L, and <148 pmol/L (3). Both sources used a different tHcy cut-off, being 
13 μmol/L or 15 μmol/L (3, 5). Only one source gave a cut-off for MMA which was 0.3 
μmol/L (3). A final cut-off for serum folate (10 nmol/L) at which tHcy levels are 
optimised was also included for further analysis (76). Table 2 outlines the cut-offs used 
and the tables throughout the thesis that utilised each cut-off. 
Mixed-effects maximum likelihood (ML) regressions with study group as a random effect 
were performed on folate biomarkers (serum folate and erythrocyte folate) vs vitamin B12 
biomarkers (serum vitamin B12, serum tHcy and serum MMA) as well as vitamin B12 
biomarkers (serum vitamin B12, serum tHcy, serum MMA) vs other variables (dietary 
energy, dietary protein and BMI) to test for associations; giving a coefficient, p-value and 
95% CI. Tests including transformed data were back transformed to give OR, p-value and 





Table 2 Deficiency measure cut-offs and location utilised 
 
Tabulation of participants based on their vitamin B12 deficiency status and their OCP use 
status was performed to determine the differences in status of users’ vs non-users. Vitamin 
B12 deficiency status was determined using the same serum vitamin B12 cut-offs (5) 
published by Hunt et al. Only serum vitamin B12 was used to determine deficiency this 
time however, as OCP participants came from both the OMN and RND studies. Due to the 
lack of tHcy and MMA data in the OMN group, it was decided that using only serum 
vitamin B12 would provide greater clarity in the results, rather than splitting the OCP users 
into groups and adding extra variables where available.  
Mixed-effects ML regressions with study group as a random effect were performed on 
vitamin B12 biomarkers (serum vitamin B12, serum tHcy, serum MMA) vs alcohol intake. 
Due to the skewed nature of alcohol intake, data was log transformed first.  
Measure Concerned Cut-off used Tables used in Reference 
 





5, 7 Carmel & Sarrai (3) 
≥148 
<148 





5 Carmel & Sarrai (3) 
≤15 
>15 










6 Selhub et al. (76) 
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Chapter Five: Results 
 
A combined total of 411 participants from three previous studies were included in the final 
analysis of our study. Table 3 outlines descriptive characteristics as well as selected 
biochemical and dietary data about the participants included in our secondary analysis 
sorted into the three groups. Box plots of vitamin B12 markers (serum vitamin B12, tHcy 
and MMA) can be seen in Appendix C.
Table 3 Descriptive characteristics of study groups 
Results reported as mean ± (SD) unless stated *p-values determined using an F-test for continuous 
variables, chi-squared test for OCP and a Fishers exact test for smoker. ELD = Elderly, OMN = Omnivores, 
RND = Random. 
 ELD (n=43) OMN (n=63) RND (n=305) P-value* 
Age 80.5 (7.6) 24.5 (4.4) 22.5 (3.9) <0.001 
BMI (kg/m2) 27.3 (7.2) 21.9 (2.8) 21.5 (2.8) <0.001 
OCP use n (%) - 21 (33) 69 (23) 0.084 
Smoker n (%) 1 (2) 2 (3) 28 (9) 0.114 
Serum folate 
(nmol/L) 
16.5 (7.5) 22.0 (9.3) 23.3 (10.3) <0.001 
Erythrocyte 
folate (nmol/L) 
1130 (476) 853 (342) 823 (297) <0.001 
Serum vitamin 
B12 (pmol/L) 
263 (110) 260 (123) 223 (105) 0.008 
Serum tHcy 
(μmol/L) 
15.0 (5.3) - 7.2 (2.3) <0.001 
Serum MMA 
(μmol/L) 
0.26 (0.13) - 0.17 (0.08) <0.001 
Dietary energy 
(kJ/day) 
8124 (1994) 12324 (5211) 9616 (3491) <0.001 
Dietary protein 
(g/day) 
86 (21) 142 (54) 111 (46) <0.001 
Alcohol 
(g/day) 
- 7.8 (11.9) 6.4 (9.5) 0.353 
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As shown in Table 3, some of the listed variables are missing where they weren’t 
measured in the respective study, namely serum tHcy and serum MMA (OMN group), and 
alcohol (ELD group). The ELD group has significantly higher (p<0.001); age, BMI and 
erythrocyte folate and significantly lower (p<0.001) serum folate than the other two 
groups. As well as this the ELD group has significantly higher (p<0.001); tHcy and MMA 
than the RND group.  
5.1 Biomarkers 
The first area of interest centres on biomarkers and the methods of determining vitamin 
B12 deficiency. Tables 4 and 5 represent the participants’ vitamin B12 status based on two 
different methods of assessing deficiency. The first, a recently published review from Hunt 
et al. (5) recommends the use of serum vitamin B12 or tHcy levels. The second, proposed 
by Carmel and Sarrai (3), uses serum vitamin B12, or a combination of serum vitamin B12 
with either MMA or tHcy.  







                                         
 
            
*indicates possible vitamin B12 deficiency. ELD and RND groups only included  
 
Serum vitamin B12 
(pmol/L) 
Serum tHcy (μmol/L) 
  ≤15                                        >15 
≥148 (n) 



















Table 4 categorises participants into one of two categories; adequate vitamin B12 status 
with a serum vitamin B12 ≥ 148 pmol/L and a tHcy ≤ 15 μmol/L, or vitamin B12 deficient 
with a serum vitamin B12 < 148 pmol/L and/or a tHcy > 15 μmol/L. Based on the serum 
vitamin B12 cut off, 78 participants (22.8%) are classed as having vitamin B12 deficiency. 
By combining the two criteria we are able to identify a further 20 participants (8%) in the 
adequate serum vitamin B12 classification with raised tHcy that would have been missed 
had we only used a serum vitamin B12 cut-off for defining deficiency, these individuals 
require further investigation for potential vitamin B12 deficiency.  Table 5 categories 
participants into one of three categories; adequate vitamin B12 status (with a serum 
vitamin B12 ≥ 258 pmol/L or a serum vitamin B12 of 148-258 in combination with a tHcy 
≤ 13 μmol/L and a MMA ≤ 0.3 μmol/L), sub-clinical vitamin B12 deficiency (with a  
Table 5: Vitamin B12 deficiency/sub-clinical deficiency using Carmel & Sarrai 










tHcy and MMA both measured in μmol/L. *indicates vitamin B12 deficiency, †indicates sub-clinical  
vitamin B12 deficiency. ELD and RND groups only included.
 
serum vitamin B12 of 148-258 pmol/L in combination with a tHcy > 13 μmol/L and/or a 
MMA > 0.3 μmol/L), or vitamin B12 deficiency (with a serum vitamin B12 < 148 
Serum vitamin 
B12 (pmol/L) 
tHcy ≤ 13  + 
MMA ≤ 0.3 
tHcy > 13 + 
MMA ≤ 0.3 
tHcy ≤ 13 + 
MMA > 0.3 
tHcy > 13   + 
MMA > 0.3 
>258 (n) 














































pmol/L). Table 5 classes 77 participants (22.9%) with deficiency. Similarly to table 4, by 
combining cut-off measures we are able to further identify individuals with adequate 
serum vitamin B12 levels that may have vitamin B12 deficiency based on metabolite 
levels and require further investigation. By using a MMA and tHcy cut-off in combination 
with a moderate serum vitamin B12 level (148-258 pmol/L) we are able to identify 22 
individuals (14% of the moderate serum vitamin B12 level group) with sub-clinical 
deficiency. In total this cut-off criteria gives a total of 99 individuals (29.5%) with 
concerning vitamin B12 status. 
Table 6 reports the percentage of individuals with vitamin B12 deficiency based on either 
serum vitamin B12 levels or tHcy levels. Based on these two measures, 55% of the ELD 
group and 25% of the RND group have potential vitamin B12 deficiency. When we 
exclude individuals whom have folate deficiency based on a low serum folate without a 
low serum vitamin B12 level these numbers drop to 39% and 24% respectively.  
Table 7 shows the percentage of individuals with optimal MMA and/or tHcy levels 
stratified by serum vitamin B12 levels. From this table we can see that of the individuals 
with a low serum vitamin B12, 83% have optimal MMA and tHcy levels. This is 
consistent with both the optimal and moderate serum vitamin B12 groups, which have 
88% and 86% of individuals respectively with optimal MMA and tHcy levels. A Pearson 
χ
2
 test showed that there were no significant differences between the three groups 
(p=0.316). When OCP users are excluded from this analysis a Pearson χ
2 
again shows that 
there were no significant differences between the three groups (p=0.214).  
Figure 3 shows the combined graphs of both, serum and erythrocyte folates vs serum 
vitamin B12, serum tHcy and serum MMA. All serum vitamin B12 and serum tHcy results 
vs serum folate and erythrocyte folate 
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Table 6 Vitamin B12 deficiency based on serum vitamin B12 and serum tHcy with accounts for serum folate status 






  low serum vitamin 
B12
1






normal serum folate 
status
3 
low serum vitamin 
B12
1
 and/or high 
tHcy
2
 with normal 
serum folate status
3 
ELD % (n) 11 (5) 48 (21) 55 (24) 30 (13) 39 (17) 
RND % (n) 24 (73) 0 (2) 25 (74) 0 (1) 24 (73) 
Total % (n) 23 (78) 7 (23) 29 (98) 4 (14) 26 (90) 
1
serum vitamin B12 < 148 pmol/L 
2
serum tHcy > 15 μmol/L 
3
serum folate ≥ 10 nmol/L 
Table 7 Concordance between MMA levels and tHcy levels stratified by serum vitamin B12 status 
 Optimal Serum Vitamin B12
1 
Moderate Serum Vitamin B12
2 






 % (n) 88 (91) 86 (134) 83 (64) 
Optimal MMA
4




5 (5) 5 (8) 4 (3) 
Optimal tHcy
5




5 (5) 6 (9) 13 (10) 
High MMA
4
 and high tHcy
5 2 (2) 3 (4) 0 (0) 
1serum vitamin B12 > 258 pmol/L 2serum vitamin B12 148-258 pmol/l 3serum vitamin B12 < 148 pmol/L 4optimal serum MMA ≤ 0.3 μmol/L, high serum 
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 were shown to be statistically significant. Serum MMA was not significantly associated 
with either serum folate (p=0.489) or erythrocyte folate (p=0.423).  
Serum vitamin B12 (pmol/L) was positively associated with both serum folate (nmol/L)  
(β =0.018 95% CI: 0.009, 0.026, p<0.001) and erythrocyte folate (nmol/L) (β =0.456 95% 
CI: 0.164, 0.747, p=0.002). Serum tHcy (μmol/L) however was negatively associated with 
both serum folate (nmol/L) (β =-0.983 95%CI: -1.246, -0.720, p<0.001) and erythrocyte 
folate (nmol/L) (β =-38.428 95%CI:-49.929, -26.927, p<0.001) 
5.2 Oral Contraceptive Pill Use 
 
The next area of interest we focused on was that of OCP user and the associations that may 
exist with vitamin B12 levels. Table 8 categories participants as having an adequate 
vitamin B12 status or as being vitamin B12 deficient (using a serum vitamin B12 cut-off 
of 148 pmol/L (5)). The table shows that 37 (42%) of the OCP users are classed as 
deficient based on serum vitamin B12 concentrations compared to 44 (16%) non-users of 
the OCP. Figure 4 displays the boxplots of serum vitamin B12 concentrations (pmol/L) 
separated by OCP user status; this clearly shows a lower median serum vitamin B12 
concentration in OCP users vs non-users. OCP use is associated with a mean decrease in 
serum vitamin B12 concentration of 72.3 pmol/L (95% CI: -93.9,-44.5, p<0.001). Neither 
tHcy (p=0.669) or MMA (p=0.595) was affected by OCP use. 
5.3 Lifestyle factors  
The next area of interest focuses on lifestyle factors that may be associated to vitamin B12 
status including; dietary factors and BMI. Table 9 highlights the associations between 
markers of vitamin B12 status and total protein intake, total energy intake and BMI. From 
the table we can see that total energy does not have any statistically significant 




































association with serum vitamin B12 (p=0.001). BMI also has a negative association with 
serum vitamin B12 which is not statistically significant (p=0.051). 
Serum vitamin B12 was also significantly negatively associated with alcohol intake 
(p<0.001), where for a 10% higher alcohol intake, this was related to a lower serum 
vitamin B12  by 1.9 pmol/L. Alcohol intake was not associated with serum tHcy but a 10% 
higher consumption of alcohol was associated with a 0.6% increase in serum MMA 
(p=0.005). 
Table 8 Serum vitamin B12 deficiency stratified by oral contraceptive use 
Serum vitamin B12 
(pmol/L) 
OCP user  
No                                        Yes 
≥148 224 (84) 52 (58) 
<148 44 (16) 37 (42) 




Figure 4 Box plot of serum vitamin B12 concentration sorted by oral contraceptive 










Table 9 Associations between serum vitamin B12, serum tHcy, and serum MMA with energy and protein intakes and BMI 
 
†Measured in ELD, OMN, and RND groups. χMeasured in ELD, RND groups *Skewed data which has been log transformed. Results are the reverse 
transformed OR and 95% CI.
 Serum vitamin B12† 




























3.844 (1.533, 6.154) 0.001 0.992 (0.983, 1.000) 0.063 0.990 (0.980, 1.001) 0.053 
BMI (kg/m2) 
 
-2.864 (-5.743, 0.016) 0.051 1.002 (.992, 1.011) 0.710 1.004 (0.992, 1.016) 0.494 
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Chapter Six: Discussion 
Our results showed that an association between different serum vitamin B12 strata and 
raised metabolites was not present. Use of the OCP was associated with a decrease in 
serum vitamin B12 levels; a decrease was also seen with increased alcohol consumption. 
Folate was shown to have a positive association with serum vitamin B12 levels.  
Our results highlighted the difficulty associated with classifying people as deficient. Of the 
two methods we employed (3, 5) in our analysis to determine the number of individuals 
with deficient vitamin B12 levels, we came across differences. While the number of 
individuals with potentially problematic vitamin B12 status was similar, Carmel and 
Sarrai’s method distinguished between those with vitamin B12 deficiency and those with 
sub-clinical deficiency using measures of serum vitamin B12, tHcy and MMA in the 
diagnostic phase (3). Hunt et al. however, only looked at deficiency, and used only serum 
vitamin B12 and tHcy as measures of deficiency (5).  
These methods were taken a step further by combining Carmel and Sarrai’s three cut-offs 
of serum vitamin B12 with the tHcy cut-off of Hunt. We developed this method further by 
adding folate status as a further stratification. In the ELD group, who had significantly 
lower serum folate levels than the larger RND group, the addition of folate changed the 
outcome of the diagnosis of deficiency drastically. By excluding individuals with moderate 
to high serum vitamin B12 levels with low tHcy levels in combination with low serum 
folate levels, the percentage of individuals in the ELD group with potential vitamin B12 
deficiency dropped from 55% to 39%.  
Folate levels and renal status have been shown to be a bigger influence on tHcy levels than 
vitamin B12 (4, 26). Folate deficiency is also known to be associated with chronic alcohol 
intake due to interference with folate absorption (77). A folate deficient diet is also 
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common in those who abuse alcohol. Folate deficiency is also seen in the elderly due to 
intestinal malabsorption (78). In populations with relatively good folate, tHcy may serve as 
a viable option as a metabolic marker of vitamin B12 deficiency, but as this cannot be 
guaranteed, it calls into question the usefulness of tHcy as a primary marker of deficiency 
like that of the methods outlined by Hunt et al. Of interest is the lack of an MMA 
diagnostic cut-off inclusion in the Hunt et al. clinical review (5). It is often concluded that 
MMA is more superior to tHcy in relation to vitamin B12 deficiency diagnosis despite 
having its own challenges (26).  
Further to the questions raised about tHcy as a biomarker, our results call into question the 
usefulness of serum vitamin B12 as a biomarker of deficiency. For some time now, serum 
vitamin B12 has been queried about its usefulness as a primary measure of vitamin B12 
status. Our results showed that regardless of vitamin B12 stratification (optimal, moderate 
or low levels), the percentage of individuals with both optimal MMA and tHcy levels 
remained the same (88%, 86% and 83% respectively). We would expect that as serum 
vitamin B12 levels decrease from optimal to moderate and then again to low that there 
would be a decrease in the percentage of individuals with optimal MMA and tHcy levels. 
This does not however happen in our population, suggesting that of the individuals with 
low serum vitamin B12 levels, the majority do not have any metabolic issues present. 
Further raising the question, should serum vitamin B12 be considered the primary marker 
of deficiency.  
Holo-transcobalamin II has been touted as a potential measure of vitamin B12 status. This 
transporter promotes cellular uptake of vitamin B12 and approximately 20 to 30% of 
plasma vitamin B12 is attached to this transporter at any given time (4). By measuring 
holo-TC II in comparison to serum vitamin B12 we are able to determine the amount of 
vitamin B12 which is biologically available for cellular uptake. Assays for holo-TC II are 
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now accurate, while a fully automated method has been available for some time (33). This 
measure has also been shown to be advantageous over serum vitamin B12 (16, 21). 
Oral contraceptive pill use was significantly associated with a decrease in mean serum 
vitamin B12 concentration of 72.3 pmol/L in individuals who took part in the OMN and 
RND studies. However, there were no metabolite (tHcy or MMA) increases associated 
with OCP use. The implications of said decrease could be potentially great if it were to be 
a true deficiency. Oral contraceptives are a relatively common medication in young 
women nowadays, and a 72.3 pmol/L decrease in serum vitamin B12 levels could have 
major consequences. Past studies have found similar results showing that the OCP 
decreases serum vitamin B12 concentrations significantly (60, 61, 79, 80). One recent 
study (81) also observed a 45.3 pmol/L reduction in serum vitamin B12 concentrations 
(p=0.036) in oral contraceptive pill users. 
There is evidence to suggest that the change in serum vitamin B12 in OCP users is due to a 
redistribution of the vitamin among transporters (62, 63). Shojania and Wylie (63) showed 
that absorption and urinary excretion of vitamin B12 remains normal in individuals using 
the OCP. Their findings also showed that OCP use was significantly associated with a 
lower total vitamin B12 binding capacity of serum and a decrease in transcobalamin I 
(haptocorrin) levels (63), which could explain the decrease in serum vitamin B12 levels. 
Shojania and Wylie suggest a decrease in transcobalamin I levels and an increase in 
transcobalamin III levels as the mechanism responsible for decreased serum vitamin B12 
levels (63). Gardyn et al. (82) also showed that in women using the OCP with low vitamin 
B12 levels, 60% had decreased transcobalamin I blood levels. In this group, deficiency 
was shown to be false based on normal urinary MMA and plasma tHcy levels. 
Furthermore, serum vitamin B12 levels returned to normal following OCP cessation for 
one month (82). Many studies hypothesise that the change in serum vitamin B12 is 
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harmless and point to biomarker (tHcy & MMA) evidence to show that this decrease has 
not caused a change in the metabolic processes associated with vitamin B12 with one 
study also showing that the decreased vitamin B12 levels did not affect bone mineral 
density as would be expected (80).  
Ultimately, our study confirms that an association between OCP use and lower serum 
vitamin B12 levels does exist, but that this is not an indicator of a true deficiency based on 
metabolite markers of vitamin B12 status. This does not however mean we can rest easy, it 
is important that we acknowledge that pernicious anaemia is still a possibility in women of 
reproductive age, and as such, a low serum vitamin B12 level in women using the OCP 
should not be discounted based on the use of this medication. Of interest would be the 
furthered research of OCP users looking into the relatively new marker of vitamin B12 
status, holo-TC II. 
Interestingly, serum and erythrocyte folate levels were both related to serum vitamin B12 
levels. This is an unexpected discovery as while vitamins B12 and folate have interrelated 
pathways in the body, they are by no means related in the diet. As previously stated, 
vitamin B12 originates from animal products, while the main dietary sources of folate 
include; green leafy vegetables, legumes, some fruits, as well as fortified cereals and cereal 
products (83).  As expected an inverse relationship between both serum and erythrocyte 
folate and tHcy levels was present, due to folates role in the methionine synthase metabolic 
process. While folate and vitamin B12 are not related in terms of where they come from in 
the diet, they have been linked in previous studies. Bailey et al (37) showed that in the 
NHANES data set, serum folate and erythrocyte folate concentrations increased with 
increasing vitamin B12 status. Two studies have showed that when individuals were 
vitamin B12 deficient, higher serum folate levels were associated with increasing tHcy and 
MMA concentrations (84, 85), suggesting a potential worsening of enzymatic function as 
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folate levels increased. Another study combining data from three cohorts has shown that in 
elderly individuals with low vitamin B12 status, increased folate levels are associated with 
impaired cognition (86). These findings raise questions about food fortification with folate, 
and beg the question of whether fortification may result in an associated rise in serum 
vitamin B12; or for those with established vitamin B12 deficiency, will be detrimental for 
metabolite levels.  
Alcohol intake was found to be negatively associated with serum vitamin B12 
concentrations, where a 10% increase in alcohol consumption was associated with a 
decrease in serum vitamin B12 concentration of 1.9 pmol/L (p<0.001). This is a 
concerning result given the population in which our participants have come from. Alcohol 
intakes were measured only in the OMN and RND group. As previously stated, Australian 
females drink in excess of the global average alcohol intake of 6.2 L of pure alcohol per 
year. The report also stated an average per day intake of 15.6 g/day in Australian females. 
With the OMN and RND studies having relatively low average daily intakes of 7.8 g/day 
and 6.4 g/day respectively, this suggests that the possible ramification of alcohol intake on 
vitamin B12 levels in Australian women could be far greater than seen in our study. The 
relationship between alcohol and vitamin B12 status has previously been explored with 
multiple studies showing a negative association between alcohol intake and vitamin B12 
status (64, 87) with both Gibson et al. and Laufer et al. showing a decrease in serum 
vitamin B12 and an increase in tHcy.  A mechanistic explanation for the relationships have 
yet to be identified, although it has been postulated that increasing alcohol consumption is 
related with decrease in dietary adequacy of B vitamins.  
A positive association between protein intake and serum vitamin B12 was shown in our 
study, with a 10g increase in dietary protein intake being associated with a 3.8 pmol/L 
increase in serum vitamin B12 concentration. Restriction of animal food group intakes is a 
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known determinant of low vitamin B12 intake (70, 88) due to vitamin B12 being located 
primarily in animal products. There appears to be little/no evidence on overall protein 
intakes association with serum vitamin B12. An association between animal protein and 
vitamin B12 status would be expected as we know dietary vitamin B12 is introduced to the 
body bound to animal protein, a factor which is important in individuals who follow a 
vegan (and to a lesser extent vegetarian) diet pattern (88). 
6.1 Strengths and Limitations 
The strength of our study lies in the inclusion of three data sets. This has given us a large 
sample size and increases the power with which we have to draw conclusions from results 
we have found. By combining the three data sets we have included a range of ages and 
broadened the characteristics of our sample population. 
Between our three data sets there are differences in our groups that make the combination 
of the data a limitation. We have to be aware that these intragroup differences are present 
when making conclusions about our results. Further limitations lay within the study 
designs themselves. It was assumed that the Australian Blue Mountains eye study FFQ 
was appropriate for the elderly group without validation in the population. This FFQ was 
originally validated for a healthy population, whereas the population used in the ELD 
study were sourced from hospital admissions. The difference in measures used between the 
studies has also proved a limitation. As the studies were completed independently, 
measures across all three do not align; this has resulted in some tests omitting sections of 
the data set due to a lack of data. The main limitation of this lay in the lack of tHcy and 
MMA data in the OMN study. Total protein was also not separated into animal protein and 
plant protein which would give better understanding of vitamin B12 in terms of total 
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animal protein in comparison to plant based protein intakes. Our sample is also a 
convenience sample and this may be a limitation.  
6.2 Conclusion 
Our study has highlighted issues surrounding serum vitamin B12 and its ability to identify 
those with deficiency. We know that serum vitamin B12 is a fairly poor measure of the 
ability to deliver vitamin B12 to tissues within the body. Serum vitamin B12 measures 
both holo-TC II and the r-binders within blood. Holohaptocorin (r-binder) is relatively 
biologically unavailable to tissues compared to holo-TC II and can mask true deficiency 
when looking at serum vitamin B12 levels. We have seen multiple instances throughout 
our study were serum vitamin B12 has proved inadequate; namely when the OCP is 
involved. Furthermore, we have seen that there are no differences in metabolite levels 
(tHcy and MMA), regardless of serum vitamin B12 status.  
The diagnosis of vitamin B12 deficiency is an area inundated with discrepancy. Without 
an ideal diagnostic test we will continue to struggle to identify those individuals with 
vitamin B12 deficiency. It is my opinion that the future of vitamin B12 and a potential 
gold standard criteria does not lie in the continued utilisation of serum vitamin B12. In 
previous decades it has become far easier to measure levels of holo-TC II in the blood. 
This measure has the potential to give us a greater insight into the body’s ability to meet 
metabolic process requirements of vitamin B12, rather than measuring total vitamin B12 
which includes both the metabolically available/unavailable sections of this vitamin. 
In order to consider holo-TC II as a future primary measure of vitamin B12 status, this 
should be our main area of concern for future research. We must investigate the grey areas 
that currently cloud this measure and determine the factors which may affect its levels 
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within the blood such as OCPs. Only by furthering our understanding of holo-TC II can we 
hope to utilise its full potential.  
By furthering our ability to identify vitamin B12 deficiency, we give ourselves the greatest 
possibility of preventing the potential issues of deficiency. As well as this, it is important 
that in the age of folate fortification we mitigate the effects of high folate intakes that have 




Chapter Seven: Application of research to dietetic practice 
From this study we can see that serum vitamin B12 is less than ideal as a primary marker 
of vitamin B12 status. Until the issues with serum vitamin B12 are rectified or a new 
marker of status becomes the norm, it is important that we examine serum vitamin B12 
results further before deciding that they are correct. Our study has shown that serum 
vitamin B12 may give either a false positive or a false negative when it comes to 
diagnosing vitamin B12 deficiency. As such, it is important to analyse each patient with a 
fresh outlook; using all the available information to determine if the serum vitamin B12 
levels fit with the assessment of the patient. Without clinical symptoms of deficiency it is 
important to look at metabolite levels to get a better picture of what is going on within the 
body. It is also important to consider other factors that may be influencing metabolite 
levels such as folate or renal status.  
As well as this, it is important to recognise that individuals using oral contraceptive pills 
may be falsely diagnosed as vitamin B12 deficient. This however does not mitigate the fact 
that women of reproductive age using OCPs are still at risk of inadequate vitamin B12 
intakes or malabsorption issues such as pernicious anaemia. As such, it is important that 
we do not dismiss all OCP users with low serum vitamin B12 levels. We must be sure that 
the decrease in serum vitamin B12 is caused by the OCP as opposed to a true deficiency.  
Another area of concern is in individuals who drink excessive amounts of alcohol. While 
these individuals are putting themselves in danger of a number of health consequences, it 
is important to remember the potential result this pattern of alcohol consumption may have 
on their vitamin B12 status.  
This research adds to the growing evidence that we may be off track with diagnosing 
vitamin B12 deficiency, this research suggests that it is time we look into other avenues of 
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diagnosing deficiency. Holo-transcobalamin II is the likely successor to the primary 
diagnostic stage of vitamin B12 deficiency. Before this can happen however, we must 
endeavour to further our understanding of this biomarker of status. We are still unable to 
utilise holo-TC II to the fullest of its potential as we are still lacking in understanding of 
the factors which affect it. As such, we must continue research in this area if we are to 
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Appendix A: Vitamin B12 content of whole foods 
 
Vitamin B12 content per 100g of whole foods. 
Food Vitamin B12 content 
(μg/100g) 
References 
Beef Liver 83 μg 36 
Lean Beef Cuts 0.7-1.5 μg 37 
Chicken Meat Trace-1.0 μg 38, 39 
Lamb Meat 1.6-1.8 μg 39 
Milk 0.3-0.4 μg 33, 39 
Eggs 0.9-1.5 μg 33, 39, 41, 42 
Shellfish ≥ 6.0 μg 44 
Fish ~3.0-159 μg 33, 36, 46 
 
Vitamin B12 in animal products 
Meat 
 
Currently the United States Department of Agriculture (USDA) database reports the 
vitamin B12 contents of cooked beef liver to be approximately 83 μg/100g (89). Quite 
differently, lean cuts of beef have relatively less B12, containing 0.7-1.5 μg/100g (90). 
This difference is not limited to beef, offal tends to have higher concentrations of B12 than 
its lean meat counterparts in all animals (89). Chicken meat has relatively small amounts 
of B12 when compared to beef, with only trace-1.0 μg/100g (45, 91). Lamb on the other 
hand is comparable to beef having 1.6-1.8 μg/100g (91). 
Milk 
Milk is a major part of many individuals’ diets, and while the vitamin B12 content (0.3-0.4 
μg/100g) of various milk varieties is not high (39, 91), it is still a significant contributor of 
vitamin B12 for many individuals. The intake of dairy products in general populations is 






Vitamin B12 content of the whole egg is around 0.9-1.5 μg/100g (39, 91, 93). Within the 
egg however the majority of the B12 is contained within the yolk (91, 94). Vitamin B12 
consumption from eggs is again generally considered to be large because of the large and 
growing consumption of eggs around the world (95). 
Shellfish 
Currently various varieties of shellfish are consumed around the world. Edible shellfish 
that siphon large amounts of vitamin B12 producing microorganisms have been shown to 
be outstanding sources of Vitamin B12, with concentrations having been shown to equal or 
exceed 6 μg/100g (96). 
Fish 
Fish (as well as shellfish) are another source of vitamin B12 which is becoming 
increasingly important around the world. Between 2006 and 2011 the annual consumption 
of fish and aquaculture increased from 114.3 million tonnes to 130.8 million tonnes and is 
expected to continue rising (97). Current USDA data shows that for general fish (salmon, 
trout, tuna etc.) a vitamin B12 content of ~ 3.0-11.0 μg/100g. There is evidence however to 
show that the content of skipjack tuna ranged from 10-159 μg/100g depending on the type 
of muscle consumed (39). Similar results were also found in another study by Nishioka 





Appendix B: Bioavailability 
 
Bioavailability of vitamin B12 in different animal products, adapted from O’Leary & Samman (45) 
Food type Subjects Vitamin B12 Content 
% Absorption, mean 
(range) 
Mutton 
3 healthy young subjects 0.9 μg per 100g portion 65 (56-77) 
2 healthy young subjects 3.03 μg per 200g portion 83 
2 healthy young subjects 




6 healthy young subjects 38 μg per serve 9.1 (5.1-19.5) 
4 older subjects 38 μg per serve 4.5 (2.4-6.0) 
5 subjects with 
pernicious anaemia 
38 μg per serve 1.8 (0-3.7) 
Chicken 3 healthy young subjects 
0.4-0.6 μg in 100g 
portion 
65 (58-74) 
0.8-1.3 μg in 200g 
portion 
63 (48-76) 
1.3-1.9 μg in 300g 
portion 
61 (49-75) 
Fish 3 healthy young subjects 
2.1 μg in 50g portion 42 
3.1 μg in 100g portion 38 
9.2 μg in 200g portion 42 
13.3 μg in 300g portion 30 
Eggs: boiled, scrambled, 
fried 
18 healthy young 
subjects 










































Appendix C: Box plots of vitamin B12 markers 
 



















































C.3 Box plot of serum MMA sorted by group 
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